Instrument Inactif

Communiqués Sevion Therapeutics Inc OTC Bulletin Board

Actions

US81834Q1040

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

11/08	Eloxx Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
20/07	Eloxx Pharmaceuticals, Inc. : Guggenheim adopte une opinion positive	ZM

Communiqués

12/08	Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update	PR
12/11/24	Eloxx Pharmaceuticals Announces Key Corporate Accomplishments	AQ
23/07/24	Eloxx Pharmaceuticals : July 2024 Investor Presentation	PU
11/07/24	Eloxx Pharmaceuticals Provides Pipeline and Financing Updates	AQ
16/04/24	Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates	AQ
13/03/24	Eloxx Pharmaceuticals : Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases	PU
13/11/23	Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update	AQ
10/10/23	Eloxx Pharmaceuticals : October 2023 Investor Presentation	PU
10/10/23	Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction	AQ
09/10/23	Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria	AQ
19/09/23	Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	AQ
18/09/23	Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	AQ
07/09/23	Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013	AQ
30/08/23	Eloxx Pharmaceuticals : Management Change - Form 8-K	PU
15/08/23	Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	AQ
14/08/23	Eloxx Pharmaceuticals : August 2023 Investor Presentation	PU
14/08/23	Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update	AQ
14/08/23	Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	AQ
03/08/23	Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement	AQ
17/07/23	Eloxx Pharmaceuticals : July 2023 Investor Presentation	PU
10/07/23	Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit	AQ
29/06/23	Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study	AQ
28/06/23	Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02	AQ
23/06/23	ELOXX PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
21/06/23	Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome	AQ